Three times in the past year, including just last month, the Food and Drug Administration has issued warnings that counterfeit cancer drugs originating overseas infiltrated the U.S. pharmaceutical supply chain, putting patients at risk.

Mike Cleland, vice president of NorthHighland, discusses what biotech and pharma companies need to do to comply with new regulations for tracking products throughout the supply chain.